Orrstown Financial Services Inc. cut its position in shares of Becton, Dickinson and Company (NYSE:BDX) by 0.3% during the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 5,623 shares of the medical instruments supplier’s stock after selling 18 shares during the period. Orrstown Financial Services Inc.’s holdings in Becton, Dickinson and were worth $1,097,000 at the end of the most recent reporting period.
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Quadrature Capital Ltd purchased a new position in shares of Becton, Dickinson and during the fourth quarter worth $944,000. UBS Asset Management Americas Inc. raised its position in shares of Becton, Dickinson and by 6.1% in the fourth quarter. UBS Asset Management Americas Inc. now owns 802,950 shares of the medical instruments supplier’s stock worth $132,928,000 after buying an additional 46,415 shares in the last quarter. Teachers Advisors LLC raised its position in shares of Becton, Dickinson and by 1.8% in the fourth quarter. Teachers Advisors LLC now owns 346,573 shares of the medical instruments supplier’s stock worth $57,375,000 after buying an additional 5,995 shares in the last quarter. Kentucky Retirement Systems purchased a new position in shares of Becton, Dickinson and during the fourth quarter worth $2,551,000. Finally, Kentucky Retirement Systems Insurance Trust Fund purchased a new position in shares of Becton, Dickinson and during the fourth quarter worth $1,138,000. 75.42% of the stock is currently owned by institutional investors and hedge funds.
Shares of Becton, Dickinson and Company (BDX) opened at 203.33 on Friday. The firm has a market capitalization of $43.37 billion, a price-to-earnings ratio of 33.77 and a beta of 1.05. The company’s 50-day moving average price is $195.21 and its 200 day moving average price is $184.45. Becton, Dickinson and Company has a 12-month low of $161.29 and a 12-month high of $204.01.
Becton, Dickinson and (NYSE:BDX) last posted its quarterly earnings data on Tuesday, May 2nd. The medical instruments supplier reported $2.30 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $2.23 by $0.07. The firm had revenue of $2.97 billion during the quarter, compared to the consensus estimate of $2.92 billion. Becton, Dickinson and had a return on equity of 25.37% and a net margin of 10.67%. The firm’s revenue was down 3.2% compared to the same quarter last year. During the same period in the prior year, the business earned $2.18 EPS. On average, equities research analysts forecast that Becton, Dickinson and Company will post $9.45 EPS for the current fiscal year.
The business also recently disclosed a quarterly dividend, which was paid on Friday, June 30th. Shareholders of record on Friday, June 9th were paid a dividend of $0.73 per share. This represents a $2.92 annualized dividend and a yield of 1.44%. The ex-dividend date of this dividend was Wednesday, June 7th. Becton, Dickinson and’s dividend payout ratio is presently 48.26%.
TRADEMARK VIOLATION NOTICE: “Orrstown Financial Services Inc. Reduces Position in Becton, Dickinson and Company (BDX)” was published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://stocknewstimes.com/2017/07/21/orrstown-financial-services-inc-reduces-position-in-becton-dickinson-and-company-bdx.html.
BDX has been the topic of a number of research reports. Jefferies Group LLC reissued a “buy” rating and issued a $200.00 price objective on shares of Becton, Dickinson and in a report on Wednesday, March 29th. Zacks Investment Research raised Becton, Dickinson and from a “hold” rating to a “buy” rating and set a $206.00 price objective on the stock in a report on Tuesday, April 11th. Royal Bank Of Canada reissued a “hold” rating and issued a $177.00 price objective on shares of Becton, Dickinson and in a report on Thursday, April 13th. Evercore ISI raised Becton, Dickinson and from an “in-line” rating to an “outperform” rating and increased their price objective for the company from $186.00 to $200.00 in a report on Monday, April 24th. Finally, Raymond James Financial, Inc. raised Becton, Dickinson and from an “outperform” rating to a “strong-buy” rating and cut their price objective for the company from $210.00 to $180.00 in a report on Friday, June 30th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company’s stock. Becton, Dickinson and has a consensus rating of “Buy” and a consensus price target of $194.69.
In other Becton, Dickinson and news, VP Jeffrey S. Sherman sold 28,765 shares of the company’s stock in a transaction that occurred on Thursday, May 25th. The stock was sold at an average price of $185.98, for a total transaction of $5,349,714.70. Following the completion of the sale, the vice president now directly owns 70,821 shares of the company’s stock, valued at approximately $13,171,289.58. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 1.40% of the stock is owned by corporate insiders.
Becton, Dickinson and Company Profile
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings.
Want to see what other hedge funds are holding BDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Becton, Dickinson and Company (NYSE:BDX).
Receive News & Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related companies with MarketBeat.com's FREE daily email newsletter.
